For colorectal cancer that has failed standard treatments, there are limited therapeutic options with short survival periods, representing a significant unmet clinical need 6.

For colorectal cancer that has failed standard treatments, there are limited therapeutic options with short survival periods, representing a significant unmet clinical need 6.

By Deidre McPhillips, CNN (CNN) — Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization ...

KAHR Bio Announces Oral Presentation of Phase 2 Study of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer at 2025 ASCO Annual Meeting ...

KAHR Bio Announces Oral Presentation of Phase 2 Study of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer at 2025 ASCO Annual Meeting PR Newswire MODI'IN, Israel, May 27, 2025 ...

Zentalis Pharmaceuticals announces poster presentation at ASCO 2025 for azenosertib in metastatic colorectal cancer.

Colonoscopies are the gold standard for detecting colon cancer, but they can cost thousands of dollars. Santa Barbara Neighborhood Clinics is filling in the gaps.

When she was 48, she noticed strange symptoms that she’d been brushing off – it turned out to be stage three colon cancer. She says detecting it in time saved her life.

Dr. Vinay Gupta, a colon oncologist at Mosaic Life Care, talks about the importance of screening for colon cancer during National Colorectal Cancer Awareness Month.

Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting The presentations will showcase ...

Post this The presentations will showcase BOT/BAL's activity across three distinct colorectal cancer settings—late-line metastatic, first-line, and neoadjuvant treatment.